XERS - CIK 0001867096
Xeris Biopharma Holdings, Inc. trades as XERS and has a market capitalization of $1.16 B, making it the #2530 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $291.85M, up 43.7% from the prior year and net income of $554.00K. This page tracks Xeris Biopharma Holdings, Inc. through 290 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years Xeris Biopharma Holdings, Inc.'s revenue grew from $20.43M to $291.85M, a compound annual growth rate of 70.2%. Net profit margin expanded from -446.0% to 0.2% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Insider trade | 4 | 2026-05-01 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| Major company event | 8-K | 2026-04-21 |
| Insider trade | 4 | 2026-04-03 |
The largest companies sharing Xeris Biopharma Holdings, Inc.'s SEC industry classification (pharmaceutical preparations).
Xeris Biopharma Holdings, Inc. (XERS) has a market capitalization of $1.16 B as of 2026-06-10, ranking #2530 among US-listed companies.
Xeris Biopharma Holdings, Inc. reported revenue of $291.85M for fiscal year 2025, an increase of 43.7% year over year.
Yes. Xeris Biopharma Holdings, Inc. reported net income of $554.00K in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.